Chiasma — Investor Presentation (January 2020)
24 slides from Chiasma's investor presentation, Jan 10, 2020
Slide 1: Chiasma Overview
Chiasma Overview NASDAQ: CHMA January 2020 Chiasma Overview Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides and the accompanying presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” a
Slide 3: Chiasma: On A Mission to Improve Patients' Lives
Chiasma: On A Mission to Improve Patients’ Lives If approved, the first oral SSA therapy in an injectable-only market Potential addressable market in acromegaly of ~$800M globally* NDA resubmitted December 26, 2019; planned Q4:2020 commercial launch Mycapssa has the potential to become the new stand
Slide 4: 2020 – A Potentially Transformational Year
2020 – A Potentially Transformational Year Commercial Launch Anticipated Q4:2020 Timing Anticipated Key Milestones Q1:2020 Mycapssa Octreotide Capsule NDA Acceptance from the FDA Q1:2020 Mycapssa OPTIMAL Phase 3 Data Presentation at ENDO Mid-2020 Publish CHIASMA OPTIMAL Phase 3 data in Peer Reviewed
Slide 5: Acromegaly U.S. Market Summary
Acromegaly U.S. Market Summary A rare and debilitating hormonal disorder caused by a benign pituitary tumor treated by surgery and pharmacologic therapy; prevalence estimated to be approximately 75 per million Somatostatin analog (SSA) injections are broadly used as first line pharmacologic treatmen
Slide 6: Current Injection Therapies Carry Significant Treatment Burdens
Current Injection Therapies Carry Significant Treatment Burdens1 Emotional Impact 36% feel loss of independence due to chronic injections Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammation (7%) Lost Work Days 16% regularly miss work for injections
Slide 7: TPE Delivery Platform
TPE® Delivery Platform …then absorbed intact at therapeutic levels. Peptide is protected by TPE® from degradation… TPE enhances oral bioavailability, potentially allowing for oral formulations of injectable-only therapies
Slide 8: Plasma Levels of Octreotide Comparable to SC Injection
Plasma Levels of Octreotide Comparable to SC Injection Data are mean ± SEM. * Octreotide subcutaneous (SC) injection = Sandostatin®, IR injection, Novartis. Octreotide SC (n=14) Octreotide Capsule (n=24) AUC(0-inf) (h´ng/mL) 13.7 (2.29) 17.0 (9.66) t1/2 (h) 2.27 (0.25) 2.66 (0.73) Data are Mean (SD)
Slide 9: Mycapssa – Robust Clinical Database
Mycapssa – Robust Clinical Database Phase 1 Trials 9 trials, 172 healthy subjects: No documented serious adverse events Abdominal discomfort was most commonly reported AE (~15%; octreotide related) Phase 3 Trials Phase 3 studies (CH-ACM-01, 302 MPOWERED, and 303 OPTIMAL); 151 + 146 + 28 patients wit
Slide 10: Mycapssa Pivotal Trial Clinical Summary
Mycapssa Pivotal Trial Clinical Summary TPE enhances oral bioavailability potentially allowing for oral formulations of injectable-only peptide therapies CHIASMA OPTIMAL phase 3 trial under a SPA agreement met its primary endpoint and all secondary endpoints NDA resubmitted December 26, 2019; antici
Slide 11: OPTIMAL Phase 3: Multinational, Randomized, Placebo-Controlled Study
OPTIMAL Phase 3: Multinational, Randomized, Placebo-Controlled Study Open Label Extension Double-blind placebo-controlled (DPC) (36 weeks) Pre-defined Withdrawal Criteria (Both Arms) IGF-1 ≥1.3 x ULN for 2 consecutive visits on the highest dose and exacerbation of clinical signs / symptoms Early ter
Slide 12: Key Clinical Information from CHIASMA OPTIMAL Trial
Key Clinical Information from CHIASMA OPTIMAL Trial The mean IGF-1 of the octreotide capsules group (n = 28) at the end of treatment was maintained within the normal range (0.97 x ULN) while it was 1.69 x ULN in the placebo group 75% of patients on octreotide capsules achieved an IGF-1 <= 1.1xULN at
Slide 13: OPTIMAL Phase 3: Primary and All Secondary Endpoints Met
OPTIMAL Phase 3: Primary and All Secondary Endpoints Met All enrolled patients completed the study Endpoints Octreotide (N=28) Placebo (N=28) P-value Primary Proportion Maintaining IGF-1 Response 58% 19% 0.008 Secondary Proportion Maintaining GH Response 78% 30% 0.001 Time to IGF-1 >1.0 × ULN Median
Slide 14: Octreotide Capsules Appeared Safe and Well Tolerated
Octreotide Capsules Appeared Safe and Well Tolerated Octreotide Capsules Placebo Subjects with: n % n % At least one TEAE 28 100.0 27 96.4 Treatment-Related TEAE 18 64.3 15 53.6 SAEs 2 7.1 1 3.6 Treatment-Related SAEs 0 0.0 0 0.0 Severe TEAEs 3 10.7 7 25.0 TEAE Leading to Study Drug Discontinuation
Slide 15: MPOWERED: Multinational, Randomized, Non-inferiority Study
MPOWERED: Multinational, Randomized, Non-inferiority Study Primary Endpoint: The proportion of patients who are biochemically controlled throughout the RCT phase. A patient will be considered biochemically controlled if their IGF-1 Time Weighted Average (TWA), during the RCT phase is < 1.3 × ULN. Ke
Slide 16: A Differentiated Rare Disease Commercial Launch Strategy
A Differentiated Rare Disease Commercial Launch Strategy Traditional Rare Disease Launch Challenges MYCAPSSA Expected Launch Advantages Patients can be hard to identify – investments needed for patient identification Doctors are critical stakeholders and may be unfamiliar with MOA or a NCE – investm
Slide 17: Expected Key Drivers For A Successful Launch
90% of patients on oral octreotide who completed the OPTIMAL trial continued into the Open Label Extension Patients experience symptoms, often later in the injection cycle, that is increasingly being recognized by HCPs Strong precedents for oral preference to injectables from relevant analogues Pati
Slide 18: Addressing the Acromegaly Market
Pituitary Centers Regional Referral Centers High Volume Community Endocrinologists Other Community Endocrinologists ~1,000 Target Accounts Addressing the Acromegaly Market 1 Orphan, Addressable U.S. Acromegaly Market Opportunity ~90% Targeted Patients Population 1 Company estimates. 2 Weighted avera
Slide 19: Patients Are Our Focus
Patients Are Our Focus Patients are Carrying the Burden Today Chiasma Case Managers Will Help Alleviate the Load Patient Education and Support Specialty Pharmacy Interface Medical Practice Interface Supply and Distribution Benefits Verification
Slide 20: Planned 2020 Approval and Launch Activities
Planned 2020 Approval and Launch Activities PDUFA Product Availability Prepare for Approval Scale Up/Launch Profile clinicians and patient flows Engage physicians, nurses, payers and patients on disease and treatment burden awareness Develop resources to facilitate switch Build supply chain Engage h
Slide 21: Key Leaders Appointed
Key Leaders Appointed SCOTT MCCONNELL VP Medical Affairs Previously Senior Director of Medical Affairs at Chiasma in 2015 & 2016; rejoined 2019 Former Medical Affairs roles at Kaledio Biosciences, Alkermes, and Cubist Pharmaceuticals / Merck & Co. Pharm.D. from Creighton University School of Pharmac
Slide 22: Mycapssa Estimated Exclusivity Timeline
Mycapssa® Estimated Exclusivity Timeline* Mid-2020* U.S. Marketing Approval Mid-2027 Expiration of U.S. Orphan Exclusivity SEPTEMBER 2029 Expiration of Formulation Patent (U.S. & EU) FEBRUARY 2036 Expiration of U.S. Issued Dosing Patent (EU patent pending) NOTES: Generics may enter the market at the
Slide 23: 2020 – A Potentially Transformational Year
2020 – A Potentially Transformational Year Well positioned for potential launch of first commercial product in 2020 Clinical Stage Company Commercial Stage Company Platform Company with Validated TPE Technology
Slide 24: Thank you
Thank you NASDAQ: CHMA January 2020